Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Funds To Rise Despite Widespread Reductions In 2011 Appropriations

This article was originally published in The Gray Sheet

Executive Summary

Despite a $37.6 billion overall cut in federal government domestic spending, a compromise fiscal 2011 funding agreement gives FDA about $107 million more dollars, totaling about $2.46 billion, compared to 2010.

You may also be interested in...

FDA Reaps $49 Million Increase For 2012 Despite Budget-Cutting Mentality

FDA receives a budget increase for fiscal 2012, including a $1 million boost for device activities, in an appropriations bill enacted Nov. 18.

FDA's Science Board To Review Comparative Effectiveness, Pharmacovigilance, Nanotech

The May 20 meeting follows a recent reorganization of the safety functions in the Center for Drug Evaluation and Research.

Shuren: Budget Woes Will Have Big Impact On FDA Device Center

Pre-market review of device applications, among other core CDRH activities, would come to a virtual halt in the event of a federal government shutdown, according to Center Director Jeffrey Shuren.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts